Three consecutive related bone marrow transplants for juvenile myelomonocytic leukaemia

Pediatr Transplant. 2005 Dec;9(6):797-800. doi: 10.1111/j.1399-3046.2005.00372.x.

Abstract

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is the only cure for juvenile myelomonocytic leukaemia (JMML), but relapse remains the major cause of failure. A second transplant may be considered a way to induce the graft vs. leukaemia effect in patients who relapse after their first HSCT. We describe a 7-month-old girl with JMML who relapsed after a first, related allo-HSCT, and who again relapsed 8 months after the second transplant, despite discontinuation of immusuppressive therapy. She underwent a third allogeneic transplant from another related donor. At the time of this report the patient is in complete remission 26 months after the third transplant. We suggest that a third allo-HSCT may be taken into consideration for JMML patients who experience relapse, even after two previous transplants.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow Transplantation / immunology
  • Bone Marrow Transplantation / physiology*
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infant
  • Leukemia, Myelomonocytic, Acute / therapy*
  • Living Donors*
  • Recurrence
  • Transplantation Chimera
  • Treatment Outcome

Substances

  • Immunosuppressive Agents